A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
← catalyst calendarNCT04895709 · readout in 1,838 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
1,109estimated
Sites
47
Countries
Australia, Canada, Germany +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-05-27 | actual | When the study began enrolling |
| Primary completion | 2031-08-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-08-31 | estimated | The whole study's end, after follow-up |
| First posted | 2021-05-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Cervical Cancer
- Gastric/Gastroesophageal Junction Adenocarcinoma
- Microsatellite Stable Colorectal Cancer
- Non-Small-Cell Lung Cancer
- Squamous Cell Carcinoma of Head and Neck
- Carcinoma, Renal Cell
- Urothelial Carcinoma
- Pancreatic Adenocarcinoma
- Melanoma
- Ovarian Neoplasms
- Triple Negative Breast Neoplasms
Interventions
- Drug: BMS-986340
- Drug: BMS-936558-01 — also filed as Nivolumab
- Drug: Docetaxel
- Drug: Pumitamig — also filed as BMS-986545, BNT327
Primary outcomes
what the primary-completion date above is the date OFIncidence of adverse events (AEs)
measured Up to 120 weeks
Incidence of serious adverse events (SAEs)
measured Up to 120 weeks
Incidence of AEs meeting protocol defined dose-limiting toxicity (DLT) criteria
measured Up to either 21 or 28 days
Incidence of AEs leading to discontinuation
measured Up to 120 weeks
Number of deaths
measured Up to 120 weeks
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed